Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05053828 · ClinicalTrials.gov registry record
Type 2 Diabetes With Antiplatelet Drugs
A clinical trial of Heart Failure and Myocardial Infarction, sponsored by Tabula Rasa HealthCare.
- Completed
- Registry status
- 173,464
- Enrollment target
- 1
- Study location
NCT05053828 is a study of Heart Failure and Myocardial Infarction that has completed, run by Tabula Rasa HealthCare. The registered enrollment target is 173,464 participants, above the 1,612-participant average among 397 other Heart Failure trials with a reported enrollment target (10661% higher). The trial reports 1 study location across 1 state.
The verdict
NCT05053828, a study of Heart Failure and Myocardial Infarction, has completed, sponsored by Tabula Rasa HealthCare.
- COMPLETED
- Registry status
- 173,464 participants
- Enrollment target
- 1
- Study location
Study Summary
Tabula Rasa HealthCare (TRHC), d/b/a CareKinesis, is the first national pharmacy that provides science-based medication risk identification and mitigation technologies and services. CareKinesis utilizes medication decision support tools and pharmacists certified in geriatrics to provide pharmacy services for various healthcare organizations including PACE organizations (described above). Presently, CareKinesis services more than 35 PACE organizations, including approximately 140 PACE sites, across the country. As a national PACE pharmacy provider since 2011, CareKinesis focuses on improving medication regimens to reduce medication-related risks while enhancing economic, clinical and humanistic outcomes. Pharmacist-led clinical services and medication safety reviews are currently being offered to PACE organizations under the direction of licensed healthcare prescribers by TRHC (CareKinesis). Through mutual data-sharing agreements, patient data will be collected retrospectively for patients satisfying the inclusion and exclusion criteria. TRHC via other programs such as the Center for Medicare \& Medicaid Enhanced Medication Therapy Management program with BlueCross BlueShield Northern Plain Alliance and ClearStone, or via collaboration as third party with other health plans can have access to de-identified patient's data. TRHC has also established an agreement with the Watson IBM database to retrieve relevant patients' information for research.
Conditions Studied
Interventions
- DRUG Antiplatelet Drug
Study Locations (1)
Florida
- Tabula Rasa Healthcare - Orlando
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 173,464 participants |
| Start Date | 2021-09-20 |
| Est. Completion | 2023-01-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05053828
The ClinicalTrials.gov registry entry for NCT05053828 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 173,464 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 1,612-participant average among 397 other Heart Failure trials with a reported enrollment target (10661% higher). The listed sponsor is Tabula Rasa HealthCare, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Heart Failure appearing as the primary indexed condition, and to 1 intervention - of which Antiplatelet Drug is the first listed.
NCT05053828 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT05053828 about?
NCT05053828 is a clinical study titled "Type 2 Diabetes With Antiplatelet Drugs". Tabula Rasa HealthCare (TRHC), d/b/a CareKinesis, is the first national pharmacy that provides science-based medication risk identification and mitigation technologies and services. CareKinesis utilizes medication decision support tools and pharmacists certified in geriatrics to provide pharmacy ser...
What is the current status of trial NCT05053828?
This trial is currently completed. The enrollment target is 173,464 participants. The study started on 2021-09-20. Estimated completion is 2023-01-30.
What conditions does trial NCT05053828 study?
This clinical trial studies the following conditions: Heart Failure, Myocardial Infarction, Type2 Diabetes, Antiplatelet Drugs.
What interventions are being tested in trial NCT05053828?
The interventions under investigation include: Antiplatelet Drug (DRUG).
Who is sponsoring clinical trial NCT05053828?
This trial is sponsored by Tabula Rasa HealthCare, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05053828 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Heart Failure
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Early Feasibility Study of the NORM™ System in Heart Failure Patients (FUTURE-HFII)
RECRUITING · NA
-
Diuretics Alone vs. Aortix Endovascular Device for Acute Heart Failure
RECRUITING · NA
-
iCardia4HF: Multi-component mHealth Intervention for Patients With Heart Failure
RECRUITING · NA
-
A Study to Evaluate Finerenone on Clinical Efficacy and Safety in Patients with Heart Failure Who Are Intolerant or Not Eligible for Treatment with Steroidal Mineralocorticoid Receptor Antagonists
RECRUITING · Phase 3
-
Circulating Markers That Underlie the Transition From Compensated Hypertrophy to Heart Failure
RECRUITING
-
Integration of Telemedicine and Home-Based Cardiac Rehabilitation: Feasibility, Efficacy, and Adherence
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.